CSF1R(+) macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094 · see citing works

Macrophage Diversity Enhances Tumor Progression and Metastasis

Qian, B., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,208 · see citing works

Tumor-Associated Macrophages: From Mechanisms to Therapy

Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089 · see citing works

Tumour-associated macrophages as treatment targets in oncology

Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,065 · see citing works

Genomic analyses identify molecular subtypes of pancreatic cancer

Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · see citing works

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170 · see citing works

Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival

Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681 · see citing works

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice

Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609 · see citing works

Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer

Öhlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M., Corbo, V., Oni, T. E., Hearn, S. A., Lee, E. J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162024 · Cited by 2,590 · see citing works

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma

Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · see citing works

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100 · see citing works

Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma

Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085 · see citing works

Integrated genomic characterization of pancreatic ductal adenocarcinoma

Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019 · see citing works

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967 · see citing works

Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy

DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715 · see citing works

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,678 · see citing works

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models

Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324 · see citing works

Macrophage Regulation of Tumor Responses to Anticancer Therapies

De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079 · see citing works

Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy

Cannarile, M. A., Weisser, M., Jacob, W., Jegg, A.-M., Ries, C. H., & Rüttinger, D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0257-y · Cited by 1,029 · see citing works

Dynamics of the immune reaction to pancreatic cancer from inception to invasion

Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990 · see citing works

Phenotype and Genotype of Pancreatic Cancer Cell Lines

Deer, E. L., González-Hernández, J., Coursen, J. D., Shea, J. E., Ngatia, J., Scaife, C. L., Firpo, M. A., & Mulvihill, S. J. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181c15963 · Cited by 936 · see citing works

Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer

Ino, Y., Yamazaki–Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., & Hiraoka, N. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.32 · Cited by 853 · see citing works

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma

Steele, C. W., Karim, S. A., Leach, J. D. G., Bailey, P. J., Upstill‐Goddard, R., Rishi, L., Foth, M., Bryson, S., McDaid, K., Wilson, Z., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.014 · Cited by 850 · see citing works

Macrophages and cancer: from mechanisms to therapeutic implications

Ostuni, R., Kratochvill, F., Murray, P. J., & Natoli, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.004 · Cited by 685 · see citing works

Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors

Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S., Hashimoto, A., Vonteddu, P., Behera, R., Goins, M. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.005 · Cited by 653 · see citing works

CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer

Xu, J., Escamilla, J., Mok, S., David, J., Priceman, S. J., West, B. L., Bollag, G. E., McBride, W. H., & Wu, L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3981 · Cited by 571 · see citing works

Stromal biology and therapy in pancreatic cancer: a changing paradigm

Neeße, A., Algül, H., Tuveson, D. A., & Gress, T. M. (2015) · Gut · doi:10.1136/gutjnl-2015-309304 · Cited by 562 · see citing works

Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles

Walz, S., Lorenzin, F., Morton, J. P., Wiese, K. E., von Eyß, B., Herold, S., Rycak, L., Dumay‐Odelot, H., Karim, S. A., Bartkuhn, M., et al. (2014) · Nature · doi:10.1038/nature13473 · Cited by 502 · see citing works

Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma

Nywening, T. M., Belt, B. A., Cullinan, D. R., Panni, R. Z., Han, B. J., Sanford, D. E., Jacobs, R. C., Ye, J., Patel, A. A., Gillanders, W. E., et al. (2017) · Gut · doi:10.1136/gutjnl-2017-313738 · Cited by 495 · see citing works

<i>STAT3</i> Plays a Critical Role in <i>KRAS</i> -Induced Pancreatic Tumorigenesis

Corcoran, R. B., Contino, G., Deshpande, V., Tzatsos, A., Conrad, C., Benes, C. H., Levy, D. E., Settleman, J., Engelman, J. A., & Bardeesy, N. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0908 · Cited by 413 · see citing works

Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation

Tape, C. J., Ling, S., Dimitriadi, M., McMahon, K. M., Worboys, J. D., Leong, H. S., Norrie, I. C., Miller, C. J., Poulogiannis, G., Lauffenburger, D. A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.029 · Cited by 369 · see citing works

Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer

Zhang, Y., Velez-Delgado, A., Mathew, E., Li, D., Mendez, F., Flannagan, K., Rhim, A. D., Simeone, D. M., Beatty, G. L., & di Magliano, M. P. (2016) · Gut · doi:10.1136/gutjnl-2016-312078 · Cited by 338 · see citing works

Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity

Stromnes, I. M., Brockenbrough, J. S., Izeradjene, K., Carlson, M. A., Cuevas, C. M., Simmons, R. M., Greenberg, P. D., & Hingorani, S. R. (2014) · Gut · doi:10.1136/gutjnl-2013-306271 · Cited by 332 · see citing works

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy

Miller, B. W., Morton, J. P., Pinese, M., Saturno, G., Jamieson, N. B., McGhee, E. J., Timpson, P., Leach, J. D. G., McGarry, L., Shanks, E. J., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404827 · Cited by 289 · see citing works

Pancreatic cancer–associated stroma production

Korc, M. (2007) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2007.05.004 · Cited by 268 · see citing works

CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma

Chao, T., Furth, E. E., & Vonderheide, R. H. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0188 · Cited by 248 · see citing works

Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers

Knudsen, E. S., Vail, P. J., Balaji, U., Ngo, H., Botros, I. W., Makarov, V., Riaz, N., Balachandran, V. P., Leach, S. D., Thompson, D. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0162 · Cited by 191 · see citing works

Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer

Alagesan, B., Contino, G., Guimarães, A. R., Corcoran, R. B., Deshpande, V., Wojtkiewicz, G. R., Hezel, A. F., Wong, K., Loda, M. F., Weissleder, R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1591 · Cited by 145 · see citing works

GEMMs as preclinical models for testing pancreatic cancer therapies

Gopinathan, A., Morton, J. P., Jodrell, D. I., & Sansom, O. J. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.021055 · Cited by 139 · see citing works

Targeting mTOR dependency in pancreatic cancer

Morran, D. C., Wu, J., Jamieson, N. B., Mrowinska, A., Kalna, G., Karim, S. A., Au, A. Y. M., Scarlett, C. J., Chang, D. K.-F., Pajak, M. Z., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-306202 · Cited by 127 · see citing works

Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model

Luheshi, N., Ulrichsen, J. C., Harper, J. A., Mullins, S., Sulikowski, M., Martin, P., Brown, L., Lewis, A. R., Davies, G. C., Morrow, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7610 · Cited by 99 · see citing works

Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation

Tape, C. J., Ling, S., Dimitriadi, M., McMahon, K. M., Worboys, J. D., Leong, H. S., Norrie, I. C., Miller, C. J., Poulogiannis, G., Lauffenburger, D. A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.079 · Cited by 80 · see citing works

Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507

Scott, D. A., Dakin, L. A., Daly, K., Valle, D. J. D., Diebold, R. B., Drew, L., Jayachandran, E., Gero, T. W., Ogoe, C. A., Omer, C. A., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.06.031 · Cited by 31 · see citing works

Erratum: Corrigendum: Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis

Nielsen, S. R., Quaranta, V., Linford, A., Emeagi, P. U., Rainer, C., Santos, A., Ireland, L., Sakai, T., Sakai, K., Kim, Y.-S., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3377 · Cited by 12 · see citing works

Pancreatic cancer: Advances and challenges

Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321 · see citing works

Molecular subtypes of pancreatic cancer

Collisson, E. A., Bailey, P., Chang, D. K., & Biankin, A. V. (2019) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/s41575-019-0109-y · Cited by 892 · see citing works

Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment

Wu, K., Lin, K., Li, X., Yuan, X., Xu, P., Ni, P., & Xu, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01731 · Cited by 691 · see citing works

Challenges and Opportunities for Pancreatic Cancer Immunotherapy

Bear, A. S., Vonderheide, R. H., & O'Hara, M. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.004 · Cited by 674 · see citing works

Activated fibroblasts in cancer: Perspectives and challenges

Caligiuri, G., & Tuveson, D. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.015 · Cited by 431 · see citing works

Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer

Halbrook, C. J., Pontious, C., Kovalenko, I., Lapienyte, L., Dreyer, S., Lee, H.-J., Thurston, G., Zhang, Y., Lazarus, J., Sajjakulnukit, P., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.001 · Cited by 419 · see citing works

Therapeutic developments in pancreatic cancer

Hu, Z., & O'Reilly, E. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 425 · see citing works

Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data

Connor, A. A., & Gallinger, S. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00418-1 · Cited by 369 · see citing works

p53, cancer and the immune response

Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333 · see citing works

Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity

Hutton, C., Heider, F., Blanco-Gomez, A., Banyard, A., Kononov, A., Zhang, X., Karim, S., Paulus-Hock, V., Watt, D., Steele, N., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.017 · Cited by 337 · see citing works

Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9

Rodríguez, E., Boelaars, K., Brown, K., Li, R. J. E., Kruijssen, L. J. W., Bruijns, S. C. M., van Ee, T., Schetters, S. T. T., Crommentuijn, M. H. W., van der Horst, J. C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21550-4 · Cited by 319 · see citing works

CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer

Pereira, B., Vennin, C., Papanicolaou, M., Chambers, C. R., Herrmann, D., Morton, J. P., Cox, T. R., & Timpson, P. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.09.010 · Cited by 309 · see citing works

Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer

(2022) · doi:10.1158/2159-8290.cd-20-1484 · Cited by 311 · see citing works

Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses

Anfray, C., Ummarino, A., Andón, F. T., & Allavena, P. (2019) · Cells · doi:10.3390/cells9010046 · Cited by 275 · see citing works

Therapeutic targeting of tumour myeloid cells

Barry, S. T., Gabrilovich, D. I., Sansom, O. J., Campbell, A. D., & Morton, J. P. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00546-2 · Cited by 305 · see citing works

Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features

Karamitopoulou, E. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0479-5 · Cited by 298 · see citing works

Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future

Christenson, E. S., Jaffee, E. M., & Azad, N. S. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30795-8 · Cited by 242 · see citing works

VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy

Yuan, L., Tatineni, J., Mahoney, K. M., & Freeman, G. J. (2021) · Trends in Immunology · doi:10.1016/j.it.2020.12.008 · Cited by 227 · see citing works

CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies

Whilding, L. M., Halim, L., Draper, B., Parente‐Pereira, A. C., Zabinski, T., Davies, D. M., & Maher, J. F. (2019) · Cancers · doi:10.3390/cancers11050674 · Cited by 209 · see citing works

Regulation and modulation of antitumor immunity in pancreatic cancer

Leinwand, J., & Miller, G. (2020) · Nature Immunology · doi:10.1038/s41590-020-0761-y · Cited by 205 · see citing works

Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer

Falcomatà, C., Bärthel, S., Schneider, G., Rad, R., Schmidt‐Supprian, M., & Saur, D. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0876 · Cited by 213 · see citing works

Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment

Looi, C.-K., Chung, F. F., Leong, C., Wong, S. F., Rosli, R., & Mai, C. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1153-8 · Cited by 206 · see citing works

CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion

Günaydın, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668349 · Cited by 205 · see citing works

Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming

Yang, S., Liu, Q., & Liao, Q. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.607209 · Cited by 202 · see citing works

Transcription factor c-Maf is a checkpoint that programs macrophages in lung cancer

Liu, M., Tong, Z., Ding, C., Luo, F., Wu, S., Wu, C., Albeituni, S., He, L., Hu, X., Tieri, D. A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131335 · Cited by 178 · see citing works

Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses

Blagih, J., Zani, F., Chakravarty, P., Hennequart, M., Pilley, S. E., Hobor, S., Hock, A. K., Walton, J. B., Morton, J. P., Gronroos, E. C., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.028 · Cited by 170 · see citing works

Uridine-derived ribose fuels glucose-restricted pancreatic cancer

Nwosu, Z. C., Ward, M. H., Sajjakulnukit, P., Poudel, P., Ragulan, C., Kasperek, S., Radyk, M. D., Sutton, D., Menjivar, R. E., Andren, A. C., et al. (2023) · Nature · doi:10.1038/s41586-023-06073-w · Cited by 162 · see citing works

Open-label, Phase I Study of Nivolumab Combined with nab -Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Wainberg, Z. A., Höchster, H. S., Kim, E. J.-H., George, B., Kaylan, A., Chiorean, E. G., Waterhouse, D. M., Guiterrez, M., Parikh, A. R., Jain, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0099 · Cited by 158 · see citing works

The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation

Martin, T. D., Patel, R. S., Cook, D. R., Choi, M. Y., Patil, A., Liang, A. C. T., Li, M. Z., Haigis, K. M., & Elledge, S. J. (2021) · Science · doi:10.1126/science.abg5784 · Cited by 156 · see citing works

Carcinogenesis of Pancreatic Ductal Adenocarcinoma

Störz, P., & Crawford, H. C. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.059 · Cited by 154 · see citing works

Recent insights into the biology of pancreatic cancer

Yao, W., Maitra, A., & Ying, H. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102655 · Cited by 125 · see citing works

Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes

Miyabayashi, K., Baker, L. A., Deschênes, A., Traub, B., Caligiuri, G., Plenker, D., Alagesan, B., Belleau, P., Li, S., Kendall, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0133 · Cited by 125 · see citing works

HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer

Brunton, H., Caligiuri, G., Cunningham, R., Upstill‐Goddard, R., Bailey, U., Garner, I., Nourse, C., Dreyer, S. B., Jones, M. D., Moran‐Jones, K., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107625 · Cited by 124 · see citing works

Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade

Nielsen, S. R., Strøbech, J. E., Horton, E. R., Jackstadt, R., Laitala, A., Bravo, M. C., Maltese, G., Jensen, A. R. D., Reuten, R., Rafaeva, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23731-7 · Cited by 119 · see citing works

3D approaches to model the tumor microenvironment of pancreatic cancer

Bort, E. T., Kieler, M., Sharma, S., Candido, J. B., & Loessner, D. (2020) · Theranostics · doi:10.7150/thno.42441 · Cited by 117 · see citing works

Tumor-associated macrophages in pancreatic ductal adenocarcinoma: therapeutic opportunities and clinical challenges

Poh, A. R., & Ernst, M. (2021) · Cancers · doi:10.3390/cancers13122860 · Cited by 106 · see citing works

Consensus, debate, and prospective on pancreatic cancer treatments

Wang, J., Yang, J., Narang, A. K., He, J., Wolfgang, C. L., Li, K., & Zheng, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01613-x · Cited by 99 · see citing works

Macrophage-Mediated Subversion of Anti-Tumour Immunity

Quaranta, V., & Schmid, M. C. (2019) · Cells · doi:10.3390/cells8070747 · Cited by 90 · see citing works

Blockade of DC-SIGN+ Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder Cancer

Hu, B., Wang, Z., Zeng, H., Qi, Y., Chen, Y., Wang, T., Wang, J., Chang, Y., Bai, Q., Xia, Y., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2254 · Cited by 90 · see citing works

Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma

Liu, S., Zhang, C., Maimela, N. R., Li, Y., Zhang, Z., Yü, P., Huang, L. J., & Zhang, Y. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1601478 · Cited by 88 · see citing works

Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

Pore, N., Wu, S., Standifer, N., Jure-Kunkel, M., de los Reyes, M., Shrestha, Y., Halpin, R., Rothstein, R., Mulgrew, K., Blackmore, S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1543 · Cited by 88 · see citing works

Drug resistance and tumor immune microenvironment: An overview of current understandings (Review)

Liu, Y., Liang, J., Zhang, Y., & Guo, Q. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5684 · Cited by 88 · see citing works

Cellular determinants and therapeutic implications of inflammation in pancreatic cancer

Stone, M. L., & Beatty, G. L. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.012 · Cited by 86 · see citing works

Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma

Gautam, S. K., Batra, S. K., & Jain, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01813-y · Cited by 88 · see citing works

Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classification systems

Dijk, F., Veenstra, V. L., Soer, E. C., Dings, M. P. G., Zhao, L., Halfwerk, J. B. G., Hooijer, G. K. J., Damhofer, H., Marzano, M., Steins, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-56826-9 · Cited by 81 · see citing works

Clinical Impact of Molecular Subtyping of Pancreatic Cancer

Zhou, X., Hu, K., Bailey, P. J., Springfeld, C., Roth, S., Kurilov, R., Brors, B., Gress, T. M., Buchholz, M., An, J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.743908 · Cited by 78 · see citing works

Macrophage-fibroblast JAK/STAT dependent crosstalk promotes liver metastatic outgrowth in pancreatic cancer

Raymant, M., Astuti, Y., Álvaro‐Espinosa, L., Green, D. M., Quaranta, V., Bellomo, G., Glenn, M. A., Chandran-Gorner, V., Palmer, D. H., Halloran, C. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47949-3 · Cited by 76 · see citing works

Tumor-Associated Macrophages in Bladder Cancer: Biological Role, Impact on Therapeutic Response and Perspectives for Immunotherapy

Leblond, M., Zdimerova, H., Desponds, E., & Verdeil, G. (2021) · Cancers · doi:10.3390/cancers13184712 · Cited by 65 · see citing works

Pancreatic cancer-associated fibroblasts modulate macrophage differentiation via sialic acid-Siglec interactions

Boelaars, K., Rodríguez, E., Huinen, Z. R., Liu, C., Wang, D., Springer, B. O., Olesek, K., Kruijssen, L. J. W., van Ee, T., Lindijer, D., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06087-8 · Cited by 72 · see citing works

Mechanisms of PDAC subtype heterogeneity and therapy response

Espinet, E., Klein, L., Puré, E., & Singh, S. K. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.08.005 · Cited by 70 · see citing works

Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma

Stromnes, I. M., Burrack, A. L., Hulbert, A., Bonson, P., Black, C., Brockenbrough, J. S., Raynor, J. F., Spartz, E. J., Pierce, R. H., Greenberg, P. D., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0448 · Cited by 69 · see citing works

Signaling in the microenvironment of pancreatic cancer: Transmitting along the nerve

Jurcak, N. R., & Zheng, L. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.010 · Cited by 67 · see citing works

Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer

Chaib, M., Chauhan, S., & Makowski, L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00351 · Cited by 62 · see citing works

Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers

Amodio, V., Mauri, G., Reilly, N. M., Bianchi, A. S., Siena, S., Bardelli, A., & Germano, G. (2021) · Cancers · doi:10.3390/cancers13112638 · Cited by 67 · see citing works

A T Cell‐Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy

Zhou, Z., der Jeught, K. V., Li, Y., Sharma, S., Yu, T., Moulana, I., Liu, S., Wan, J., Territo, P. R., Opyrchal, M., et al. (2023) · Advanced Science · doi:10.1002/advs.202300548 · Cited by 65 · see citing works

Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC

Zhou, X., An, J., Kurilov, R., Brors, B., Hu, K., Peccerella, T., Roessler, S. K., Pfütze, K., Schulz, A., Wolf, S., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00628-6 · Cited by 66 · see citing works

Improving outcomes of patients with pancreatic cancer

Dreyer, S. B., Beer, P. A., Hingorani, S. R., & Biankin, A. V. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01019-9 · Cited by 66 · see citing works

Integrated in silico and 3D in vitro model of macrophage migration in response to physical and chemical factors in the tumor microenvironment

Lee, S. W. L., Seager, R. J., Litvak, F., Spill, F., Sieow, J. L., Leong, P. H., Kumar, D., Tan, A. S. M., Wong, S. C., Adriani, G., et al. (2020) · Integrative Biology · doi:10.1093/intbio/zyaa007 · Cited by 60 · see citing works

Light-responsive nanomedicine for cancer immunotherapy

Kang, W., Liu, Y., & Wang, W. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.016 · Cited by 63 · see citing works

Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies

Pham, T. N. D., Shields, M., Spaulding, C., Principe, D., Li, B., Underwood, P. W., Trevino, J., Bentrem, D., & Munshi, H. (2021) · Cancers · doi:10.3390/cancers13030440 · Cited by 58 · see citing works

Loss of Rnf43 accelerates kras-mediated neoplasia and remodels the tumor immune microenvironment in pancreatic adenocarcinoma

Hosein, A. N., Dangol, G., Okumura, T., Roszik, J., Rajapakshe, K., Siemann, M., Zaid, M., Ghosh, B., Monberg, M., Guerrero, P. A., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.12.273 · Cited by 61 · see citing works

Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities

Jain, A., & Bhardwaj, V. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i39.6527 · Cited by 59 · see citing works

Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer

Saung, M. T., Muth, S. T., Ding, D., Thomas, D. L., Blair, A. B., Tsujikawa, T., Coussens, L. M., Jaffee, E. M., & Zheng, L. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0435-6 · Cited by 59 · see citing works

ZBED2 is an antagonist of interferon regulatory factor 1 and modifies cell identity in pancreatic cancer

Somerville, T. D. D., Xu, Y., Wu, X., Maia-Silva, D., Hur, S. K., de Almeida, L. M. N., Preall, J. B., Koo, P. K., & Vakoc, C. R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921484117 · Cited by 60 · see citing works

Multiomic characterization of pancreatic cancer-associated macrophage polarization reveals deregulated metabolic programs driven by the GM-CSF-PI3K pathway

Boyer, S., Lee, H.-J., Steele, N., Zhang, L., Sajjakulnukit, P., Andren, A., Ward, M. H., Singh, R., Basrur, V., Zhang, Y., et al. (2022) · eLife · doi:10.7554/elife.73796 · Cited by 56 · see citing works

Myeloid Cell Mediated Immune Suppression in Pancreatic Cancer

Kemp, S. B., di Magliano, M. P., & Crawford, H. C. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.07.006 · Cited by 55 · see citing works

STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1

Proia, T. A., Singh, M., Woessner, R. D., Carnevalli, L. S., Bommakanti, G., Magiera, Ł., Srinivasan, S. S., Grosskurth, S. E., Collins, M. P., Womack, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1066 · Cited by 55 · see citing works

Pancreatic melatonin enhances anti-tumor immunity in pancreatic adenocarcinoma through regulating tumor-associated neutrophils infiltration and NETosis

Chan, Y.-T., Tan, H., Lu, Y., Zhang, C., Cheng, C., Wu, J., Wang, N., & Feng, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.020 · Cited by 54 · see citing works

Macrophage and Neutrophil Interactions in the Pancreatic Tumor Microenvironment Drive the Pathogenesis of Pancreatic Cancer

Pratt, H. G., Steinberger, K. J., Mihalik, N. E., Ott, S., Whalley, T., Szomolay, B., Boone, B. A., & Eubank, T. D. (2021) · Cancers · doi:10.3390/cancers14010194 · Cited by 51 · see citing works

Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma

Schmiechen, Z. C., & Stromnes, I. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613815 · Cited by 53 · see citing works

Immunotherapy of pancreatic cancer

Sunami, Y., & Kleeff, J. H. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.03.006 · Cited by 51 · see citing works

Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer

Vonderheide, R. H., & Bear, A. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.605619 · Cited by 48 · see citing works

Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer

Sadozai, H., Acharjee, A., Eppenberger‐Castori, S., Gloor, B., Gruber, T., Schenk, M., & Karamitopoulou, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643529 · Cited by 47 · see citing works

Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis

Koll, F. J., Banek, S., Kluth, L., Köllermann, J., Bankov, K., Chun, F. K.-H., Wild, P. J., Weigert, A., & Reis, H. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03949-3 · Cited by 47 · see citing works

The dynamic interactions between the stroma, pancreatic stellate cells and pancreatic tumor development: Novel therapeutic targets

Farran, B., & Nagaraju, G. P. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.07.001 · Cited by 46 · see citing works

The Role of the Microbiome in Pancreatic Cancer

Miyabayashi, K., Ijichi, H., & Fujishiro, M. (2022) · Cancers · doi:10.3390/cancers14184479 · Cited by 45 · see citing works

Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels

Du, J., Gu, J., & Li, J. (2020) · Bioscience Reports · doi:10.1042/bsr20200401 · Cited by 44 · see citing works

Depletion of Macrophages Improves Therapeutic Response to Gemcitabine in Murine Pancreas Cancer

Buchholz, S., Goetze, R. G., Singh, S. K., Ammer‐Herrmenau, C., Richards, F. M., Jodrell, D. I., Buchholz, M., Michl, P., Ellenrieder, V., Heßmann, E., et al. (2020) · Cancers · doi:10.3390/cancers12071978 · Cited by 44 · see citing works

Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer

Veghini, L., Pasini, D., Fang, R., Delfino, P., Filippini, D., Neander, C., Vicentini, C., Fiorini, E., Lupo, F., D’Agosto, S. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54975-8 · Cited by 43 · see citing works

Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunotherapy

Zuo, C., Baer, J. M., Knolhoff, B. L., Belle, J. I., Liu, X., de la Lastra, A. A., Fu, C. F., Hogg, G. D., Kingston, N. L., Breden, M. A., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20212062 · Cited by 43 · see citing works

Spatially restricted tumour-associated and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer

Karamitopoulou, E., Wenning, A. S., Acharjee, A., Zlobec, I., Aeschbacher, P., Perren, A. A., & Gloor, B. (2023) · Gut · doi:10.1136/gutjnl-2022-329371 · Cited by 42 · see citing works

The role of eIF4F-driven mRNA translation in regulating the tumour microenvironment

Bartish, M., Abraham, M. J., Gonçalves, C., Larsson, O. S., Rolny, C., & Rincon, S. V. D. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00567-5 · Cited by 39 · see citing works

High‐grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF‐1

Steins, A., van Mackelenbergh, M. G., van der Zalm, A. P., Klaassen, R., Serrels, B., Goris, S. G., Kocher, H. M., Waasdorp, C., de Jong, J. H., Tekin, C., et al. (2020) · EMBO Reports · doi:10.15252/embr.201948780 · Cited by 38 · see citing works

Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact

Gutiérrez, M. L., Muñoz‐Bellvís, L., & Órfão, A. (2021) · Cancers · doi:10.3390/cancers13174451 · Cited by 38 · see citing works

Ping-Pong—Tumor and Host in Pancreatic Cancer Progression

Mu, W., Wang, Z., & Zöller, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01359 · Cited by 37 · see citing works

The dark side of immunotherapy: pancreatic cancer

Mucciolo, G., Roux, C., Scagliotti, A., Brugiapaglia, S., Novelli, F., & Cappello, P. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.13 · Cited by 37 · see citing works

Cell Lineage Infidelity in PDAC Progression and Therapy Resistance

Malinova, A., Veghini, L., Real, F. X., & Corbo, V. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.795251 · Cited by 35 · see citing works

Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer

Kajiwara, Y., Tazawa, H., Yamada, M., Kanaya, N., Fushimi, T., Kikuchi, S., Kuroda, S., Ohara, T., Noma, K., Yoshida, R., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03334-x · Cited by 36 · see citing works

Cell-selective proteomics segregates pancreatic cancer subtypes by extracellular proteins in tumors and circulation

Swietlik, J. J., Bärthel, S., Falcomatà, C., Fink, D., Sinha, A., Cheng, J., Ebner, S., Landgraf, P., Dieterich, D. C., Daub, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38171-8 · Cited by 36 · see citing works

PAD4 controls tumor immunity via restraining the MHC class II machinery in macrophages

Pitter, M. R., Kryczek, I., Zhang, H., Nagarsheth, N., Xia, H., Wu, Z., Tian, Y., Okła, K., Liao, P., Wang, W., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113942 · Cited by 34 · see citing works

Protein Kinase A Catalytic Subunit Is a Molecular Switch that Promotes the Pro-tumoral Function of Macrophages

Na, Y. R., Kwon, J. W., Kim, D.-Y., Chung, H., Song, J., Jung, D., Quan, H., Kim, D., Kim, J., Ju, Y. W., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107643 · Cited by 34 · see citing works

Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma

Skorupan, N., Domínguez, M. P., Ricci, S. L., & Alewine, C. (2022) · Cancers · doi:10.3390/cancers14174209 · Cited by 32 · see citing works

From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer

Bazzichetto, C., Conciatori, F., Luchini, C., Simionato, F., Santoro, R., Vaccaro, V., Corbo, V., Falcone, I., Ferretti, G., Cognetti, F., et al. (2020) · Cells · doi:10.3390/cells9020309 · Cited by 33 · see citing works

Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages

Samain, R., Brunel, A., Douché, T., Fanjul, M., Cassant‐Sourdy, S., Rochotte, J., Cros, J. F., Neuzillet, C., Raffenne, J., Duluc, C., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.01.008 · Cited by 32 · see citing works

Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation

Arnoletti, J. P., Reza, J. A., Rosales, A., Monreal, A. J., Fanaian, N., Whisner, S., Srivastava, M., Rivera-Otero, J., Yu, G., Phanstiel, O., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265725 · Cited by 33 · see citing works

Activation of STING in the pancreatic tumor microenvironment: A novel therapeutic opportunity

Chamma, H., Vila, I. K., Taffoni, C., Turtoï, A., & Laguette, N. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215694 · Cited by 33 · see citing works

Strategies to overcome myeloid cell induced immune suppression in the tumor microenvironment

Cao, J. H., Chow, L., & DOW, S. W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1116016 · Cited by 32 · see citing works

Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma

Graziano, V., Dannhorn, A., Hulme, H., Williamson, K., Buckley, H., Karim, S. A., Wilson, M., Lee, S. Y., Kaistha, B. P., Islam, S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006457 · Cited by 29 · see citing works

Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I–Related Plexiform Neurofibromas

Boal, L. H., Glod, J. W., Spencer, M., Kasai, M., Derdak, J., Dombi, E., Ahlman, M., Beury, D. W., Merchant, M. S., Persenaire, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1696 · Cited by 31 · see citing works

Tumor-associated macrophages (TAMs): Constructing an immunosuppressive microenvironment bridge for pancreatic ductal adenocarcinoma (PDAC)

Liu, R., Li, J., Liu, L., Wang, W., & Jia, J. (2024) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.07.004 · Cited by 31 · see citing works

Defining the Ontogeny and Functions of Macrophages in Pancreatic Ductal Adenocarcinoma

Zhu, Y. (2017) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k79c6vvn

Abstract B61: CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models

Zhu, Y., Knolhoff, B. L., Melissa, M., Brian, W., David, L., & DeNardo, D. G. (2015) · Cancer Research · doi:10.1158/1538-7445.panca2014-b61 · Cited by 1 · see citing works

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models

Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324 · see citing works

Macrophage proliferation machinery leads to PDAC progression, but susceptibility to innate immunotherapyPreprint

Zuo, C., Baer, J. M., Knolhoff, B. L., Belle, J. I., Liu, X., Hogg, G. D., Fu, C. F., Kingston, N. L., Brenden, M. A., de la Lastra, A. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.08.467770 · Cited by 3 · see citing works

Tumor-associated macrophages in pancreatic ductal adenocarcinoma: Therapeutic opportunities and clinical challenges

Poh, A. R., & Ernst, M. (2021) · La Trobe University · doi:10.26181/14907924